Camilla Bardram Johnbeck

Rigshospitalet | rigshospitalet · Department of Clinical Physiology, Nuclear Medicine and PET

Objective We present an algorithm to estimate the delay between a tissue time-activity curve and a blood input curve at a single-voxel level tested on whole-body data from a long-axial field-of-view scanner with tracers of different noise characteristics. Methods Whole-body scans of 15 patients divided equally among three tracers, namely [ ¹⁵ O]H...

Frequent somatostatin receptor PET, for example, 64Cu-DOTATATE PET, is part of the diagnostic work-up of patients with neuroendocrine neoplasms (NENs), resulting in high accumulated radiation doses. Scan-related radiation exposure should be minimized in accordance with the as-low-as-reasonably achievable principle, for example, by reducing injected...

Background Segmentation of neuroendocrine neoplasms (NENs) in [ ⁶⁴ Cu]Cu-DOTATATE positron emission tomography makes it possible to extract quantitative measures useable for prognostication of patients. However, manual tumor segmentation is cumbersome and time-consuming. Therefore, we aimed to implement and test an artificial intelligence (AI) netw...

Purpose: Patients with neuroendocrine neoplasms (NEN) engage in lifelong follow-up with frequent somatostatin receptor PET, e.g. [64Cu]Cu-DOTATATE PET, and continued measures to reduce radiation exposures should be in pursued in accordance with the as-low-as-reasonably-achievable (ALARA) principle. We therefore aimed to determine the lowest achiev...

PET/computed tomography (CT) imaging increasingly is used in neuroendocrine neoplasms (NENs) for diagnosis, staging, monitoring, prognostication, and choosing treatment. Somatostatin PET analog tracers have added to the specificity by obtaining higher affinity to somatostatin receptors with 68Ga-labeled or 64Cu-labeled DOTA peptides compared with s...

Patients with neuroendocrine neoplasms (NEN) have heterogeneous somatostatin receptor expression with highly differentiated lesions having higher expression. Receptor expression of the total tumor burden may be visualized by somatostatin receptor imaging, e.g. 64Cu-DOTATATE PET/CT. Assessment of maximal lesion uptake is associated with progression-...

The recent introduction of solid-state detectors in clinical positron emission tomography (PET) scanners has significantly improved image quality and spatial resolution and shortened acquisition time compared to conventional analog PET scanners. In an initial evaluation of the performance of our newly acquired Siemens Biograph Vision 600 PET/CT (di...

Accurate grading of patients with neuroendocrine neoplasms (NENs) is essential for risk stratification and optimal choice of therapy. Currently, grading is based on histologically assessed degree of tumor proliferation. The aim of the present study was to assess the long-term prognostic value of 18F-FDG PET imaging for risk stratification of NENs a...

64Cu-DOTATATE PET/CT imaging 1 hour (h) post-injection (p.i.) is excellent for lesion detection in patients with neuroendocrine neoplasms (NEN). We hypothesized that the imaging time window can be extended up to 3h p.i. without significant differences in the number of lesions detected. Methods From a prospective study, we compared, on a head-to-hea...

Overexpression of somatostatin receptors (SSTRs) in patients with neuroendocrine neoplasms (NENs) is used for both diagnosis and treatment. Receptor density may reflect tumor differentiation and thus be associated with prognosis. Noninvasive visualization and quantification of SSTR density is possible by SSTR imaging (SRI) using PET. Recently, we i...

Methods: Fifty-nine NET patients were scanned both with (64)Cu-DOTATATE and (68)Ga-DOTATOC PET and computed tomography (CT) and compared on a head-to-head basis. Discordant lesions were verified during at least 30 months of follow-up. Results: A total of 701 lesions were concordantly detected on both (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT sca...

Methods: One-hundred patients were PET-scanned with both (18)F-FLT and (18)F-FDG within the same week, and the prognostic value of a positive scan was examined in terms of progression free survival (PFS) and overall survival (OS). The correlation between the Ki67 index and (18)F-FLT uptake was investigated. Results: Thirty-seven percent of patie...

Background: The somatostatin receptor subtype 2 (SSTR2) is expressed on macrophages, an abundant cell type in the atherosclerotic plaque. Visualization of SSTR2, for oncological purposes, is frequently made using the 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraaceticacid (DOTA)-derived somatostatin analogues DOTA-Tyr3-octreotide (DOTATOC) or DOTA-T...

Rationale: Local plaque macrophage proliferation and monocyte production in hematopoietic organs promote progression of atherosclerosis. Therefore, non-invasive imaging of proliferation could serve as a biomarker and monitor therapeutic intervention. Objective: To explore (18)F-fluorothymidine ((18)F-FLT) PET-CT imaging of cell proliferation in...

Heart muscle cells produce peptide hormones such as natriuretic peptides. Developing hearts also express the gene for the classic gut hormone cholecystokinin (CCK) in amounts similar to those of the gut and the brain. However, cardiac expression of other peptides than natriuretic peptides has only been suggested using transcriptional measures or me...

Neuroendocrine tumors have shown rising incidence mainly due to higher clinical awareness and better diagnostic tools over the last 30 years. Functional imaging of neuroendocrine tumors with PET tracers is an evolving field that is continuously refining the affinity of new tracers in the search for the perfect neuroendocrine tumor imaging tracer. (...

The mTOR inhibitor everolimus has shown promising results in some but not all neuroendocrine tumors. Therefore, early assessment of treatment response would be beneficial. In this study, we investigated the in vivo and in vitro treatment effect of everolimus in neuroendocrine tumors and evaluated the performance of 18F-FDG and the proliferation tra...

Background Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3’-deoxy-3’-[18F]fluorothymidine ([18F]FLT) and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomogra...

APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-in...

Combined PET/MRI systems are now commercially available and are expected to change the medical imaging field by providing combined anato-metabolic image information. We believe this will be of particular relevance in imaging of cancer patients. At the Department of Clinical Physiology, Nuclear Medicine & PET at Rigshospitalet in Copenhagen we insta...

Introduction: Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate early changes in cell proliferation and glucose uptake by use of 3’-deoxy-3’-[18F]fluorothymidine (FLT) and 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomograp...

Background and aim: Everolimus (RAD001), an oral mTOR inhibitor has shown promising results in the treatment of several types of cancer including neuroendocrine tumors. With the expanding numbers of clinical treatment protocols there is a need for early, non-invasive predictors of treatment response. We hypothesized that PET imaging with the prolif...

The aim of our study was to perform a prospective study that compared the diagnostic ability of V/Q single photon emission computer tomography (V/Q-SPECT), V/Q-SPECT combined with low-dose computed tomography (CT) and pulmonary multidetector computed tomography(MDCT)-angiography in patients suspected of having pulmonary embolism (PE) using a dedica...

The aim of our study was to perform a prospective study that compared the diagnostic ability of V/Q single photon emission computer tomography (V/Q-SPECT), V/Q-SPECT combined with low-dose computed tomography (CT) and pulmonary multidectector computed tomography(MDCT)-angiography in patients suspected of having pulmonary embolism (PE) using a dedic...

The diagnosis of pulmonary embolism (PE) is usually established by a combination of clinical assessment, D-dimer testing, and imaging with either pulmonary ventilation-perfusion (V/Q) scintigraphy or pulmonary multidetector CT (MDCT) angiography. Both V/Q SPECT and MDCT angiography seem to have high diagnostic accuracy. However, only limited data d...